Gainesville, Ga. poultry vaccine site received carbon neutrality certification, becoming the first site US Animal Health Products Manufacturing Plant Will Declare Carbon Neutral

DULUTH, Ga., April 22, 2022 /PRNewswire/ — Boehringer Ingelheim US Animal Health today announced that its poultry vaccines site in Gainesville, Ga., received carbon neutral certification, the first of its US sites to achieve this designation. The site, which produces nearly 60 billion poultry vaccines each year, is Boehringer Ingelheim’s first major manufacturing site in the United States and its third global site to become carbon neutral.

“Boehringer Ingelheim is committed to making the company, surrounding communities and the world more environmentally sustainable, now and for future generations,” said Randolph LeggPresident and Chief Commercial Officer at Boehringer Ingelheim Animal Health UNITED STATES Inc. “The completion of our Gainesville site inspires our entire global team as we move towards our goal of becoming carbon neutral across all company operations by 2030 (Scope 1 and Scope 2)1.”

the Gainesville The site has been working towards more sustainable operations since 2017, when they noticed emissions equaled over 1,000 homes. Electricity is one of the biggest emitters of on-site emissions, so the site team purchased green electricity from Georgia Power to power the site more sustainably and eliminate nearly 80 % of carbon emissions.

To achieve carbon neutral status, the site team made additional changes, including:

  • Installation of solar panels above the car park to harness the power of the sun,
  • Replacement of fluorescent bulbs with energy efficient LED bulbs,
  • Installed dimmers and occupancy sensors that turn off lights when rooms are not in use,
  • Purchase of an electric vehicle to circulate on the site and installation of a charging station,
  • Installation of smart meters to measure electricity consumption, which helps to identify energy savings, and
  • Replacement of equipment insulation to reduce heat and energy losses.

To offset the few remaining carbon emissions, the company purchased environmental project carbon credits from Climate Seed. Site employees chose to invest in the Noles Sud Avoided Conversion Forest Project in North Carolina and a reforestation project in the Kasigau Corridor in Kenya.

With these changes, the company entered into a contract with GermanyTÜV, an independent third-party certification services company, to review and certify the site for carbon neutrality. The company received carbon neutral certification on April 11. The certification process confirms that the site has reduced and offset greenhouse gas emissions for 2021. Certification must be reviewed annually and is based on emissions from the previous year.

“We are delighted that the updates we have implemented at this facility and the support of our employees have earned us the carbon neutral certification,” said Andy Brehm, site manager at the Boehringer Ingelheim plant in Gainesville. “It’s important to us and everyone at the site that we work towards a more sustainable future, for our communities and the people and animals we serve.”

“This shift to carbon neutrality helps protect the environment we live in,” said Lara Sheley, head of the US swine and poultry divisions at Boehringer Ingelheim Animal Health. “And when the environment is healthy, people and animals are healthier.”

Boehringer Ingelheim sites across the United States are implementing a significant process towards carbon neutrality as part of Boehringer Ingelheim Sustainable development for generations initiative. The website at Saint-Joseph, Mo. runs on wind power. In North Brunswick, NJ, the site purchased green energy. In Barcelona, Porto Rico, the site will use natural gas to generate electricity, which will create steam and hot water that can be used in daily operations. The Corporate and Human Pharma US headquarters in Ridgefield, Conn.runs on renewable energy.

About “Sustainability – for generations”

Boehringer Ingelheim operates to meet the needs of human and animal health. This makes the company uniquely positioned to address the intersecting challenges of sustainability. The “Sustainable Development – ​​For Generations” framework is based on three pillars: “Healthier”, “Greener” and “More Potential”. Through these pillars, Boehringer Ingelheim is implementing 20 initiatives worldwide to drive business contributions and impact. These are in line with the United Nations Sustainable Development Goals. To successfully achieve these goals, the company has renewed its committed approach to working in partnership, calling for the multi-stakeholder collaboration needed to address complex global challenges.

About Boehringer Ingelheim Animal Health UNITED STATES

Boehringer Ingelheim Animal Health is working on breakthrough innovation for the prediction, prevention and treatment of disease in animals. For veterinarians, pet owners, producers and governments in over 150 countries, we offer a broad, innovative portfolio of products and services to improve the health and well-being of pets and livestock. .

As a global leader in the animal health industry and part of the family business Boehringer Ingelheim, we take a long-term view. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are also healthier. By utilizing the synergies between our Animal Health and Human Pharma businesses and delivering value through innovation, we improve the health and well-being of both.

Boehringer Ingelheim Animal Health has deep roots in the United States. St. Joseph, Missouri, over 100 years ago, it expanded to encompass seven sites. The Boehringer Ingelheim Animal Health portfolio contains widely used and respected vaccines, pest control products and therapeutics for companion animals, horses and livestock, including NexGard®, Heartgard®, Pyramid® Presponse®, VAXXITEK®, CircoFLEX ® and Prascend®.

Learn more about Boehringer Ingelheim Animal Health UNITED STATES on bi-animalhealth.com


  1. Scope 1 – All emissions directly from business activities and under the control of Boehringer Ingelheim. Scope 2 – Indirect emissions created by energy purchased and used by Boehringer Ingelheim for business operations.

SOURCE Boehringer Ingelheim Animal Health UNITED STATES Inc.

Boyd S. Abbott